Pharmacotherapy of obesity in complex diseases

Pulipati, Vishnu Priya; Pannain, Silvana

doi:10.1111/cob.12497

Cited by 9 publications

(4 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The epidemic of obesity is associated with a steady rise in drug consumption in order to treat several associated diseases such as type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, dyslipidemia and osteoarthritis [ 1 , 2 ]. In addition, numerous drugs are currently being developed in order to specifically treat nonalcoholic fatty liver disease (NAFLD), which is frequently associated with obesity and overweight [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Acetaminophen-Induced Hepatotoxicity in Obesity and Nonalcoholic Fatty Liver Disease: A Critical Review

Begriche¹,

Penhoat²,

Bernabeu-Gentey³

et al. 2023

Livers

View full text Add to dashboard Cite

The epidemic of obesity, type 2 diabetes and nonalcoholic liver disease (NAFLD) favors drug consumption, which augments the risk of adverse events including liver injury. For more than 30 years, a series of experimental and clinical investigations reported or suggested that the common pain reliever acetaminophen (APAP) could be more hepatotoxic in obesity and related metabolic diseases, at least after an overdose. Nonetheless, several investigations did not reproduce these data. This discrepancy might come from the extent of obesity and steatosis, accumulation of specific lipid species, mitochondrial dysfunction and diabetes-related parameters such as ketonemia and hyperglycemia. Among these factors, some of them seem pivotal for the induction of cytochrome P450 2E1 (CYP2E1), which favors the conversion of APAP to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). In contrast, other factors might explain why obesity and NAFLD are not always associated with more frequent or more severe APAP-induced acute hepatotoxicity, such as increased volume of distribution in the body, higher hepatic glucuronidation and reduced CYP3A4 activity. Accordingly, the occurrence and outcome of APAP-induced liver injury in an obese individual with NAFLD would depend on a delicate balance between metabolic factors that augment the generation of NAPQI and others that can mitigate hepatotoxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Acetaminophen-Induced Hepatotoxicity in Obesity and Nonalcoholic Fatty Liver Disease: A Critical Review

Begriche¹,

Penhoat²,

Bernabeu-Gentey³

et al. 2023

Livers

View full text Add to dashboard Cite

show abstract

“…104 The best thing about orlistat is that it can be taken by people suffering with diabetes, hypertension and hypercholesterolemia. 105,106 In addition to steatorrhea, side effects include flatulence, fecal incontinence, stomach pain, and liver toxicity. 107 Orlistat decreases fat-soluble vitamin absorption, so multi-vitamin supplements are recommended with it.…”

Section: Fda/ema Approved Drugs For Obesitymentioning

confidence: 99%

Recent advancements in pharmacological strategies to modulate energy balance for combating obesity

Pati,

Sendh,

Sahu

et al. 2023

RSC Med. Chem.

View full text Add to dashboard Cite

show abstract

“…Obesity is a medical disorder that causes an increase in body fat, putting individuals at risk of health problems such as heart disease, T2DM, and cancer [55,56]. BBR is a drug that could be used to treat obesity.…”

Section: Anti-obesitymentioning

confidence: 99%

Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends

et al. 2022

View full text Add to dashboard Cite

Traditionally, herbal compounds have been the focus of scientific interest for the last several centuries, and continuous research into their medicinal potential is underway. Berberine (BBR) is an isoquinoline alkaloid extracted from plants that possess a broad array of medicinal properties, including anti-diarrheal, anti-fibrotic, antidiabetic, anti-inflammatory, anti-obesity, antihyperlipidemic, antihypertensive, antiarrhythmic, antidepressant, and anxiolytic effects, and is frequently utilized as a traditional Chinese medicine. BBR promotes metabolisms of glucose and lipids by activating adenosine monophosphate-activated protein kinase, stimulating glycolysis and inhibiting functions of mitochondria; all of these ameliorate type 2 diabetes mellitus. BBR has also been shown to have benefits in congestive heart failure, hypercholesterolemia, atherosclerosis, non-alcoholic fatty liver disease, Alzheimer’s disease, and polycystic ovary syndrome. BBR has been investigated as an interesting pharmacophore with the potential to contribute significantly to the research and development of novel therapeutic medicines for a variety of disorders. Despite its enormous therapeutic promise, the clinical application of this alkaloid was severely limited because of its unpleasant pharmacokinetic characteristics. Poor bioavailability, limited absorption, and poor water solubility are some of the obstacles that restricted its use. Nanotechnology has been suggested as a possible solution to these problems. The present review aims at recent updates on important therapeutic activities of BBR and different types of nanocarriers used for the delivery of BBR in different diseases.

show abstract

Pharmacotherapy of obesity in complex diseases

Cited by 9 publications

References 112 publications

Acetaminophen-Induced Hepatotoxicity in Obesity and Nonalcoholic Fatty Liver Disease: A Critical Review

Acetaminophen-Induced Hepatotoxicity in Obesity and Nonalcoholic Fatty Liver Disease: A Critical Review

Recent advancements in pharmacological strategies to modulate energy balance for combating obesity

Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends

Contact Info

Product

Resources

About